A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of CKD-506 Administered to Adult Subjects With Moderate-to- Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
Latest Information Update: 04 Nov 2021
At a glance
- Drugs CKD 506 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chong Kun Dang
- 26 Dec 2019 New trial record